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MANUSCRIPT 
 
Background: 
In East and Southern Africa, where 5-10% have chronic hepatitis B virus (HBV) 
infection, incidence of human immunodeficiency virus (HIV) infection remains 
unacceptably high. This introduces challenges and opportunities for implementation 
of HBV care and treatment. We now describe new HIV diagnoses made within an 
HBV monoinfection cohort in Zambia and their relevance to broader HBV policy 
implementation. 
 
HBV monoinfection cohort in Zambia: 
At a hospital in Lusaka, adults (18+ years) who were hepatitis B surface antigen-
positive and HIV-negative (based on an antibody assay 12 months prior) enrolled in 
a prospective cohort. At enrollment, a physical examination was performed and we 
measured HBV DNA, hepatitis B e antigen (HBeAg), and ALT, which was repeated 
every 3-6 months thereafter. HBV therapy initiation, with fixed-dose combination 
tenofovir disoproxil fumarate (TDF) and lamivudine – the recommended regimen in 
Zambia, was based on World Health Organization (WHO) criteria (1). All patients 
were followed-up every 3-6 months, and HIV testing was repeated yearly.  
 
Description of new HIV diagnoses: 
Among 160 participants (median age 33 years, 71.9% male), 5 (3.1%) tested HIV-
positive during follow-up (Table 1). Patient 1 was a 28-year-old man with HBeAg-
negative hepatitis (HBV DNA 23,017 IU/ml and ALT 79 U/L) at baseline. He initiated 
HBV therapy 6 months post-enrollment and at 1 year, HBV DNA was undetectable 
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(<20) and ALT had reduced to 33 U/L. However, repeat HIV testing was positive. HIV 
RNA was undetectable. Patients 2-4 were men, aged 23-38 years-old, non-cirrhotic, 
and presumed inactive HBV carriers (HBV DNA <2,000 IU/ml and ALTs of 26-33 
U/L) who did not meet criteria for HBV therapy. At their 1-year visits, HIV-positivity 
was ascertained. Patient 5 was a 45-year-old man with HBeAg-positive hepatitis 
(HBV DNA >170,000,000 IU/ml and ALT 100 U/L) who initiated HBV therapy 2 
months post-enrollment. Medication adherence was good per pharmacy records and 
HBV DNA was undetectable at 2 years. However, at 3.5 years on therapy, HIV-
positivity was diagnosed. At that time HBV DNA was 3,417 IU/ml and HIV-1 RNA 
was 4,523 copies/ml. Sanger sequencing of HIV-1 revealed M184V, a mutation that 
confers high-level resistance to lamivudine, and the thymidine analog mutations 
(TAMs) M41L and T215Y, which, when combined, confer low-level resistance to 
TDF.  
 
Discussion: 
Current WHO HBV guidelines lack guidance on the timing and frequency of HIV 
testing (1), nor do they mention the potential of HBV therapy to prevent new HIV 
infections, i.e., pre-exposure prophylaxis (PrEP). In an HBV cohort in Zambia, 3.1% 
became HIV positive, providing insights for HBV therapy in high HIV prevalence 
settings. Patient 1 seroconverted between enrollment and HBV therapy initiation and 
although he suppressed HIV RNA on HBV therapy, this scenario could have 
spawned HIV drug resistance (HIVDR). On the basis of this case, we now re-confirm 
HIV status at the first dispensation of HBV therapy, regardless last negative HIV test 
date. Patients 2-4 were ineligible for HBV therapy, posing potential missed 
opportunities to prevent HIV infection. Only a small fraction (5-25%) of chronic HBV 
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cases in Africa meet HBV therapy criteria (2). HIV incidence could potentially be 
reduced by expanding eligibility for HBV therapy, for example, to immune tolerant 
patients who are often not treated despite increasing evidence of potential liver 
damage (3). Also, the Zambian Ministry of Health recommends long-term HBV 
therapy for any HBsAg-positive individual referred for HIV PrEP due to high 
perceived HIV risk. Patient 5 had suboptimal medication adherence, the major 
barrier to PrEP effectiveness (4), and the presence of the M184V mutation could be 
explained by selection pressure of HBV therapy. As HBV therapy does not select for 
TAMs, this patient probably acquired an HIV infection with pre-existing mutations. On 
the basis of these cases we recommend that HBV programs in settings with high HIV 
incidence ensure strong access to HIV testing. The potential public health benefits of 
HBV therapy in moderate/high prevalence settings should be investigated.  
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Table 1. Demographic and clinical characteristics of HBV monoinfected Zambian adults who became HIV-antibody positive during follow-up 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Age 28 years 30 years 23 years 38 years 45 years 
Sex  male male male male male 
Enrollment HBV DNA, U/L  23,017 53 85 232 170,000,000 
Enrollment HBeAg status non-reactive non-reactive reactive missing reactive 
Enrollment ALT level, U/L 79 33 26 26 110 
HBV disease stage immune active inactive carrier inactive carrier inactive carrier immune active 
Initiation of HBV therapy* yes no no no yes 
Time from enrollment to start of HBV therapy  5 months N/A N/A N/A 2 months 
Reduced medication adherence (per pharmacy records) no N/A N/A N/A no 
Time from enrollment to HIV-positivity 18 months 8 months 8 months 4 months 44 months 
HBV DNA at HIV diagnosis, IU/ml <20 missing missing missing 3,417 
HIV RNA at HIV diagnosis, copies/ml <20  missing missing missing 4,523 
*HBV therapy was prescribed when patients met World Health Organization criteria and consisted of fixed dose combination tenofovir disoproxil 
fumarate and lamivudine. Abbreviations: HBV, hepatitis B virus; HIV, human immunodeficiency virus; HBeAg, hepatitis B e antigen; ALT, alanine 
aminotransferase; N/A, not applicable 
 
